Medscape Medical News Conference News ASCO 2026 Selpercatinib Cuts Recurrence Risk in Early RET+ Non-Small Cell Lung Cancer Will Pass May 31, 2026

https://www.medscape.com/viewarticle/selpercatinib-cuts-recurrence-risk-early-ret-non-small-cell-2026a1000i25 Adjuvant selpercatinib improves event-free survival (EFS) in patients with early-stage, RET fusion-positive non-small cell lung cancer (NSCLC) who have undergone definitive surgery or radiation, based on results of the first phase 3 trial to use a RET inhibitor as adjuvant therapy. https://www.medscape.com/c25/p14/american-society-clinical-oncology-asco-2026-2026a1000c7g